

Design, Optimization and Synthesis of Certain Heterocyclic Compounds with Potential Targeted Anticancer Activity.

Thesis presented by:

Rasha Mohamed Mohamed Mohamed Aly

*Master Degree In pharmaceutical Sciences,
Faculty of Pharmacy, Ain Shams University, 2013
Assistant Researcher of Pharmaceutical Chemistry, NODCAR
(National Organization of Drug Control And Research)*

*Submitted for the partial fulfillment of the PhD Degree
In Pharmaceutical Sciences (Pharmaceutical Chemistry)*

Under the supervision of:

Prof. Dr.Dalal Abd Alrahman Abou El-Ella

Professor of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University

Dr. Rabah Ahmed Taha Serya

*Assistant professor of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams
University*

Dr. Amira Mohamed El-Metwally

*Assistant professor of Organic Chemistry, National Organization of Drug Control And
Research*

**Faculty of Pharmacy,
Ain Shams University,
Cairo, 2017**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

تصميم وتعظيم وتشبيد بعض المركبات غير متجانسة الحلقة التي لها فاعلية محتملة ضد السرطان.

رسالة مقدمة من :

الصيدلانية/ رشاد محمد محمد محمد علي

ماجستير العلوم الصيدلانية - كلية الصيدلة - جامعة عين شمس - ٢٠١٣
باحث مساعد بالهيئة القومية للرقابة والبحوث الدوائية

لإستيفاء الحصول علي درجة الدكتوراه في العلوم الصيدلانية
(الكيمياء الصيدلانية)

تحت إشراف:

أ.د./ دلال عبد الرحمن أبو العلا
أستاذ الكيمياء الصيدلانية- كلية الصيدلة - جامعة عين شمس

أ.م./ رباح أحمد طه سريه
أستاذ مساعد الكيمياء الصيدلانية - كلية الصيدلة - جامعة عين شمس

أ.م./ أميرة محمد المتولي
أستاذ مساعد الكيمياء العضوية - الهيئة القومية للرقابة و البحوث الدوائية

كلية الصيدلة
جامعة عين شمس
القاهرة - ٢٠١٧

Acknowledge

Firstly, I thank and praise **ALLAH**
in a compromise to complete access to this work.

I am heartily thankful and sincerely appreciated to **Prof. Dr. Dalal A.Abou El Ella**,
Professor of Pharmaceutical Chemistry, Ain shams University, and Dean of the faculty of
pharmacy ,Nahda University for her kind suggestion of the point of this research, her
supervision with accuracy and great experience in designing and writing this thesis. She's
profoundly thanked for her encouragement, continuous guidance, motivation, enthusiasm,
immense knowledge, valuable advice and support during all stages of this work and also
in my life. No words can describe my gratitude to her.

I would like to express my sincere gratitude to **Dr. Rabah A. T. Serya**,
Assistant Professor of Pharmaceutical Chemistry, Ain shams University, for her
supervision, great support, continuous encouragement and guidance.

Really, i am proud with her supervision and great effort for me.

I am extremely grateful and thankful to **Dr. Amira Mohamed El- Metwally**,
Assistant professor of Organic Chemistry, NODCAR, for her supervision, untiring help,
valuable assistance, chemicals support and constant encouragement throughout the
whole practical work and during writing this thesis.

I would like to thank **Dr.Ahmed Esmat**,
Lecturer of Pharmacology and Toxicology, faculty of pharmacy,
Ain shams University, for his great effort in performing the biological activity tests.
He's profoundly thanked for his effort, support, and experience.

Finally, I would like to thank all the members of pharmaceutical chemistry department for
their appreciation.

Dedication



My Parents

I have to thank my **Mother** and **Father**
for their love, support in my life, believing in me
and praying for me. Without whom I could not
have made this thesis.

Thank you both for giving me strength to reach
the stars and chase my dreams.

I dedicate this thesis for you with all my love.



My Sisters

Many thanks for my sisters;

Marwa, Eman and Heba

for their love, support, encourage
and praying for me.



My Friends

Thanks to all my friends, especially

Amany Morsi, Reham Elsaied, Dina Mohamed,
Ghada El-Hag, Hanady Amer and Sara El-monaieri.
who always help, encourage and support me.

Thanks for all my family and every person encouraging,
supporting and helping me to introduce this thesis.

THANKS GOD

Contents	i
<i>List of figures</i>	<i>v</i>
<i>List of tables</i>	<i>x</i>
<i>List of abbreviations</i>	<i>xi</i>
<i>Abstract</i>	<i>xiv</i>
1. Introduction	1
1.1. Cancer definition	2
1.2. Cancer cases distribution	2
1.3. Tumorigenesis, tumor growth and oncogenes	3
1.4. Cancer types	5
1.5. Cancer causes	5
1.6. Cancer treatment	6
1.6.1. Surgery	6
1.6.2. Radiotherapy	7
1.6.3. Chemotherapy	7
1.6.3.1. Cell kill and cell cycle	7
1.6.3.2. Classification of Chemotherapeutic agents	8
1.6.3.2.1. Antimetabolites that interfere with nucleic acid biosynthesis	8
1.6.3.2.2. DNA alkylating agents	8
1.6.3.2.3. Anticancer agents that modulate hormone action	9
1.6.3.2.4. Anticancer drugs acting via radical species: radiotherapy and photodynamic therapy of cancer	10
1.6.3.2.5. Anticancer drugs that interact with DNA minor groove	10
1.6.3.2.6. DNA topoisomerase inhibitors	12
1.6.3.2.7. Anticancer drugs targeting tubulin and microtubules	13
1.6.3.2.8. Drugs that inhibit tumor cell signaling pathways for their growth and proliferation	14
1.7. Protein kinases	14
1.7.1. Tyrosine kinases	15
1.7.1.1. Receptor Tyrosine Kinases (RTKs)	15
1.7.1.2. EGFR and cancer	16
1.7.1.3. Intracellular signaling networks activated by EGFR	16
1.7.1.4. EGFR structure	17
1.7.1.5. The binding of EGF to EGFR	19
1.7.2. The ATP-binding site regions	20
1.7.3. Design of selective kinase inhibitors	20
1.7.4. Kinase inhibitors	21
1.7.4.1. Types of kinase inhibitors	21
1.7.4.2. FDA-approved small-molecule kinase inhibitors	21
1.7.4.2.1. Irreversible kinase inhibitors	22
1.7.4.2.2. Reversible kinase inhibitors	23

1.7.5. Quinazolines as reversible receptor tyrosine kinase (RTK) inhibitors.....	24
1.7.6. Quinolines as anticancer drugs.....	25
1.7.6.1. Quinolines as protein kinase inhibitors.....	25
1.7.6.2. Quinolines as EGFR Inhibitors.....	26
2. Rationale and Design.....	28
2.1. Rationale, design and optimization of quinoline EGRF TK inhibitors.....	29
2.2. Synthetic schemes.....	35
2.2.1. Scheme (1) for synthesis of starting materials: N-(3- or 4-substituted phenyl)-2-cyanoacetamides Va-e	35
2.2.2. Scheme (2) for synthesis of of intermediates: 3-(4-acetylphenylamino)- N-(3-or 4-substituted phenyl)-2-cyanoacrylamides Vla-e	35
2.2.3. Scheme (3) for synthesis of intermediates: 3, 4, 6-trisubstituted quinolines VIIAa-e and *VIIBa, b	36
2.2.4. Scheme (4) for synthesis of intermediates: 5-(3- or 4-substituted phenyl)furan-2- carbaldehydes VIIla-c	36
2.2.5. Scheme (5) for synthesis of final compounds: 6-(3-substituted acryloyl)-4- (3-or-4-substituted phenylamino)quinolines IXa-o , *IXp	37
2.2.6. Scheme (6) for synthesis of final compounds: 6-(5-amino-4-cyano- thiophen-3-yl)quinolines Xa-c , 6-(2-aminothiazol-4-yl)quinolines XIa-c and carbonitrile analogue *Xd/*XIId	38
2.2.7. Scheme (7) for synthesis of final compounds: 6-(5-substituted amino- 4-cyano-thiophen-3-yl)quinolines *XIIa & *XIIIa and carbonitrile analogue *XIIb/*XIIIb	39
2.2.8. Scheme (8) for synthesis of final compound: 6-acetyl-4-(4-(benzyloxy)- phenylaminoquinoline-3-carboxamide XIV	39
3. Results and discussion.....	40
3.1. Chemistry.....	41
3.1.1. Scheme (1).....	41
3.1.2. Scheme (2).....	42
3.1.3. Scheme (3).....	44
3.1.4. Scheme (4).....	46
3.1.5. Scheme (5).....	48
3.1.6. Scheme (6).....	51
3.1.7. Scheme (7).....	55
3.1.8. Scheme (8).....	58
3.2. Biological evaluation.....	60
3.2.1. Biochemical assay (EGFR protein kinase inhibitor activity).....	60
3.2.1.1. Evaluation of the newly synthesized class (1) target compounds.....	60
3.2.1.1.1. Evaluation of the newly synthesized class (1) target compounds at concentration 10 μ M against EGFR TK target.....	60
3.2.1.1.2. Further optimization of compound IXo showing the highest EGFR inhibition effect in class (1).....	64
3.2.1.2. Evaluation of the newly synthesized class (2) target compounds.....	65

3.2.1.2.1.	Evaluation of the newly synthesized compounds of class (2) at concentration 10 μ M against EGFR TK target.....	65
3.2.1.2.2.	Further optimization of the most potent EGFR inhibitor of class (2), Xb	68
3.2.2.	Cytotoxicity assay	70
3.2.3.	Correlation between cytotoxicity assay and EGFR assay.....	71
3.2.4.	Final Conclusion.....	72
4.	Molecular modeling	73
4.1.	Introduction.....	74
4.2.	The molecular modeling techniques.....	77
4.2.1.	Reported common five-features pharmacophore and library of primary proposed compounds.....	77
4.2.2.	Mapping of the proposed compounds.....	79
4.2.3.	Docking and binding energy calculations.....	81
4.2.4.	Design of further optimization of the most potent EGFR inhibitors of class (1) & (2) target compounds.....	85
4.2.4.1.	Design of further optimization of the compound having the highest EGFR inhibition effect in class (1), IXo	85
4.2.4.2.	Design of further optimization of the most potent EGFR inhibitor of class (2), Xb	87
4.3.	Results and discussion: overlaying and alignment correlation.....	89
4.4.	Methodology	99
4.4.1.	Reported pharmacophore model and library of proposed compounds.....	99
4.4.1.1.	Design of proposed compounds library.....	99
4.4.1.2.	Mapping of the proposed compounds.....	99
4.4.2.	Docking (C-Docker).....	99
4.4.2.1.	Loading the EGFR enzyme from protein data bank (PDB).....	99
4.4.2.2.	Preparation of enzyme structure.....	99
4.4.2.3.	Identifying the binding pocket of each enzyme structure.....	99
4.4.2.4.	Display lead-protein interactions in each enzyme structure.....	100
4.4.2.5.	Docking of each native ligand in its own active site.....	100
4.4.2.6.	Displaying the docking scores.....	100
4.4.2.7.	Validation of the ligands (Lapatinib (27) and Gefitinib (28)) docking and selection of proper binding pose.....	100
4.4.2.8.	Docking in the PDB: IXKK.....	100
4.4.2.8.1.	Docking of the lead compound (45) and proposed compounds.....	100
4.4.2.8.2.	Loading the lead compound (45) and proposed compounds.....	100
4.4.2.8.3.	Interactive docking.....	100
4.4.2.8.4.	Displaying the docking scores.....	100
4.4.3.	Binding energy.....	101
4.4.3.1.	Minimization.....	101
4.4.3.2.	Binding energy calculations.....	101
4.4.3.3.	Displaying the binding pattern of Lapatinib (27)/ lead compound (45) /and promising compounds (2D and 3D).....	101

4.4.4. Redocking in the PDB:2ITY.....	101
4.4.4.1. Docking of the lead compound (45) and proposed compounds.....	101
4.4.4.1.1. Loading the lead compound (45) and proposed compounds.....	101
4.4.4.1.2. Interactive docking.....	101
4.4.4.1.3. Displaying the docking scores.....	101
5. Experimental.....	102
5.1. Chemistry.....	103
5.1.1. Materials and methods.....	103
5.1.2. Synthesis.....	104
5.2. Biological evaluation of compounds.....	151
5.2.1. Biochemical Assay (EGFR protein kinase inhibitor activity).....	151
5.2.1.1. Evaluation of synthesized compounds at concentration 10 μ M against EGFR TK target.....	151
5.2.1.1.1. Materials: quality control and reagents.....	151
5.2.1.1.2. Methodology.....	151
5.2.1.1.3. Protein kinase (PK) assays.....	151
5.2.1.2. EGFR IC ₅₀ Determination for six potent EGFR inhibitors.....	152
5.2.2. Cytotoxicity assessment.....	153
5.2.2.1. Methodology.....	153
5.2.2.1.1. Cell culture.....	153
5.2.2.1.2. SRB cytotoxicity assay.....	153
6. Appendix.....	154
6.1. Appendix-I: Fitting values, -CDOCKER Interaction Energy, Binding energy, 2D and 3D Interactions of reference compounds {Lapatinib (27), Gefitinib (28) & lead compound (45)}, target compounds class (1) { IXa-o } and class (2) { Xa-c , XIa-c and XIV }.....	155
6.2. Appendix-II: Fitting values, -CDOCKER Interaction Energy, Binding energy, 2D and 3D Interactions of carbonitriles and extended analogues of the most potent target compounds class (1) & (2): { IXp , XIIa , b and XIIIa }.....	183
6.3. Appendix-III: The results of antitumor activity assays (MCF-7 IC ₅₀) of some potent compounds in comparison to their EGFR IC ₅₀ and EGFR % activity changes { IXo , IXp , Xb , XIIa , XIIb and XIV }	188
7. References.....	191

List of figures:

Figure (1): Most common cancers worldwide in 2012.....	2
Figure (2): Cancer mortality in Egypt 2016 according to WHO.....	3
Figure (3): The acquired hallmarks and biological capabilities during tumor development.....	3
Figure (4): Cancer development.....	4
Figure (5): Benign versus malignant tumors.....	4
Figure (6): Types of cancer.....	5
Figure (7): The role of genes and environment in the development of cancer.....	6
Figure (8): Cell cycle phases extended over the interval between the midpoint mitosis and the subsequent end point in mitosis in daughter cell. P; prophase, M; metaphase, A; anaphase, T; telophase.....	7
Figure (9): Mechanism of action of alkylating agents.....	9
Figure (10): Reversible interactions with DNA.....	11
Figure (11): The binding of Distamycin A (18) with DNA.....	11
Figure (12): Intercalation of Ethidium bromide (20) in the DNA base pairs stack.....	12
Figure (13): Structure of microtubules.....	13
Figure (14): (a) Microtubules and tubulin dimers dynamic equilibrium, (b) The interaction of chemotherapeutic agents that stabilize or destabilize microtubules.....	13
Figure (15): The role of protein kinases.....	15
Figure (16): EGFR Role in intracellular signaling networks activation through a combination of stimulatory signals (black arrows), inhibitory (red lines) signals, key positive feedback loops (blue circular arrows) and negative feedback loops (red circular arrows).....	17
Figure (17): Structure of EGFR.....	17
Figure (18): I–IV domains of extracellular region of EGFR (without ligand).....	18
Figure (19): The tyrosine kinase domain of EGFR showing the N-lobe and C-lobe flanking the activation loop and active site cleft.....	18
Figure (20): Ligand-induced dimerization and activation process of EGFR.....	19
Figure (21): EGFR pathway, displaying downstream signal transduction cascades that are regulated by ligand binding to EGFR.....	19
Figure (22): The ATP-binding site of kinases.....	20